ARD-101
Prader-Willi Syndrome (hyperphagia)
Key Facts
About Aardvark Therapeutics
Aardvark Therapeutics is pioneering a novel approach to metabolic health by targeting the neurological distinction between hunger and appetite. The company's lead program, ARD-101, is advancing through clinical development with a focus on hyperphagia in Prader-Willi Syndrome and potential expansion into general obesity. With a strengthened board featuring industry veterans from Merck and Akamara, Aardvark is positioning itself to become a leader in hunger-focused therapeutics for both rare and common metabolic conditions.
View full company profileAbout Aardvark Therapeutics
Aardvark Therapeutics is pioneering a novel approach to metabolic health by targeting the neurological distinction between hunger and appetite. The company's lead program, ARD-101, is advancing through clinical development with a focus on hyperphagia in Prader-Willi Syndrome and potential expansion into general obesity. With a strengthened board featuring industry veterans from Merck and Akamara, Aardvark is positioning itself to become a leader in hunger-focused therapeutics for both rare and common metabolic conditions.
View full company profileAbout Aardvark Therapeutics
Aardvark Therapeutics is pioneering a novel approach to metabolic health by targeting the neurological distinction between hunger and appetite. The company's lead program, ARD-101, is advancing through clinical development with a focus on hyperphagia in Prader-Willi Syndrome and potential expansion into general obesity. With a strengthened board featuring industry veterans from Merck and Akamara, Aardvark is positioning itself to become a leader in hunger-focused therapeutics for both rare and common metabolic conditions.
View full company profileAbout Aardvark Therapeutics
Aardvark Therapeutics is pioneering a novel approach to metabolic health by targeting the neurological distinction between hunger and appetite. The company's lead program, ARD-101, is advancing through clinical development with a focus on hyperphagia in Prader-Willi Syndrome and potential expansion into general obesity. With a strengthened board featuring industry veterans from Merck and Akamara, Aardvark is positioning itself to become a leader in hunger-focused therapeutics for both rare and common metabolic conditions.
View full company profile